Cargando…

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials

BACKGROUND: The bone-forming metastases of prostate cancer result from complex stromal–epithelial interactions within the tumour microenvironment. Autocrine–paracrine signalling pathways between prostate cancer epithelial cells, osteoblasts, and osteoclasts stimulate aberrant bone remodelling, and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Som, A, Tu, S-M, Liu, J, Wang, X, Qiao, W, Logothetis, C, Corn, P G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493771/ https://www.ncbi.nlm.nih.gov/pubmed/23033003 http://dx.doi.org/10.1038/bjc.2012.436

Ejemplares similares

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
por: de la Piedra, C, et al.
Publicado: (2013)

Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation
por: Voorzanger-Rousselot, N, et al.
Publicado: (2006)

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
por: Alcaraz, A, et al.
Publicado: (2013)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer
por: Verset, L, et al.
Publicado: (2013)

Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival
por: Kuang, B-H, et al.
Publicado: (2013)

Melanoma sentinel node biopsy and prediction models for relapse and overall survival
por: Mitra, A, et al.
Publicado: (2010)

Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Cheng, et al.
Publicado: (2017)

Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer
por: Brown, M D, et al.
Publicado: (2010)

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients
por: Qiao, G-B, et al.
Publicado: (2005)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival
por: Li, Z, et al.
Publicado: (2011)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Osteopontin is a marker for cancer aggressiveness and patient survival
por: Weber, G F, et al.
Publicado: (2010)

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients
por: El Hajj, P, et al.
Publicado: (2013)

Identification of markers of prostate cancer progression using candidate gene expression
por: Larkin, S E T, et al.
Publicado: (2012)

Asporin is a stromally expressed marker associated with prostate cancer progression
por: Rochette, Annie, et al.
Publicado: (2017)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
por: Payne, R E, et al.
Publicado: (2012)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer
por: Kelly, P, et al.
Publicado: (2012)

The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
por: Dalton, L E, et al.
Publicado: (2013)

Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
por: Dudderidge, T J, et al.
Publicado: (2007)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

CD133 expression is an independent prognostic marker for low survival in colorectal cancer
por: Horst, D, et al.
Publicado: (2008)

Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
por: Fox, P, et al.
Publicado: (2013)

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
por: Ragnum, H B, et al.
Publicado: (2015)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells
por: Ueno, K, et al.
Publicado: (2009)

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
por: Ali, A M G, et al.
Publicado: (2011)

Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer
por: Sjöberg, Elin, et al.
Publicado: (2016)

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer
por: Balanathan, P, et al.
Publicado: (2009)

Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone
por: Endo-Munoz, L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_687bh2feupidnmqagsvfedaaf6